Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.
| Brand name | NEBIVOLOL |
| Generic name | NEBIVOLOL |
| Active ingredient(s) | NEBIVOLOL HYDROCHLORIDE |
| Distributed by / for | Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520 |
| NDC | 59651-137-30 |
| Full product label | Nebivolol Tablets, 2.5. mg, 30-count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520. NDC: 59651-137-30 |
| Recalling firm | Aurobindo Pharma USA Inc |
| Distribution | Nationwide in the USA |
| Recall initiated | 2024-12-06 |
| Report date | 2024-12-25 |
| Recall completed | — |
| Recall number | D-0149-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | East Windsor NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗